6 completed, 3 withdrawn, 2 terminated, 1 active not recruiting. 12 Phase 2.
By phase and status
Follow ostarine: new trials by email Literature Review of ostarine trials Research Report on ostarine
Trials (filtered) newest first · largest first
All 12 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss Enobosarm, Semaglutide (Wegovy) weekly injection - Obesity & Overweight, Mobility Disability | Phase 2 | Active not recruiting | 239 | 2026-03-26 | 2026-09-04 |
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt Enobosarm, Semaglutide - Muscle Loss, Obesity | Phase 2 | Completed | 168 | 2024-04-29 | 2025-09-17 |
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence GTx-024 - Stress Urinary Incontinence | Phase 2 | Withdrawn | | 2018-06-28 | 2024-03-01 |
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence GTx-024, Matching Placebo - Stress Urinary Incontinence | Phase 2 | Withdrawn | | 2018-05-28 | 2023-09-14 |
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence GTx 024, Placebo - Stress Urinary Incontinence | Phase 2 | Completed | 491 | 2017-08-21 | 2021-03-24 |
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab - Androgen Receptor Positive, Estrogen Receptor Negative | Phase 2 | Completed | 18 | 2017-06-01 | 2024-02-20 |
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass GTx-024 9 or 18 mg - ER+ and AR+ Breast Cancer | Phase 2 | Withdrawn | | 2016-04-01 | 2024-02-26 |
GTx-024 as a Treatment for Stress Urinary Incontinence in Women GTx-024 - Stress Urinary Incontinence | Phase 2 | Completed | 19 | 2016-01-01 | 2021-02-01 |
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer GTx-024 - ER+ and AR+ Breast Cancer | Phase 2 | Completed | 136 | 2015-08-01 | 2020-12-09 |
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) GTx-024 - Triple Negative Breast Cancer | Phase 2 | Terminated | 32 | 2015-06-01 | 2020-11-18 |
Phase II Study of GTx024 in Women With Metastatic Breast Cancer GTx-024 9mg - Metastatic Breast Cancer | Phase 2 | Terminated | 22 | 2013-04-01 | 2024-03-08 |
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. GTx-024, Placebo - Cachexia | Phase 2 | Completed | 159 | 2007-05-01 | 2014-07-11 |
Conditions studied
Urinary Incontinence, Stress (4) · Muscular Atrophy (2) · Obesity (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Cachexia (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Overweight (1)
Sponsors
GTx (9) · Veru Inc. (2) · City of Hope Medical Center (1)
Countries
United States (12) · Canada (1)
Top investigators
Kenneth Peters, MD (2) · Beth A Overmoyer, MD (1) · Hannah M Linden, MD (1) · Hope S Rugo, MD (1) · Kenneth M Peters, MD (1) · Kenneth M. Peters, MD (1) · Mayzie Johnston, PharmD (1) · Yuan Yuan (1)
Results publications
PMID 23499390, PMID 38342115